Master dataINID | Criterion | Field | Content |
---|
| Type of IP right | SART | Patent |
| Status | ST | Pending/in force |
21 | DE file number | DAKZ | 60 2007 055 908.1 |
96 | EP file number | EAKZ | 13 16 4403.1 |
97 | EP publication number | EPN | 2662091 |
54 | Designation/title | TI | Anti-P-Selektin-Antikörper und Verfahren zu ihrer Verwendung für die Behandlung von Entzündungserkrankungen |
51 | IPC main class | ICM (ICMV) | A61K 39/395 (2006.01) |
51 | IPC secondary class(es) | ICS (ICSV) | C07K 16/28 (2006.01) |
22 | DE application date | DAT | Nov 30, 2007 |
96 | EP application date | EAT | Nov 30, 2007 |
43 | Date of first publication | OT | Nov 13, 2013 |
| Date of publication of grant | PET | Aug 22, 2018 |
71/73 | Applicant/owner | INH | Novartis AG, Basel, CH; Oklahoma Medical Research Foundation, Oklahoma City, Okla., US |
72 | Inventor | IN | McEver, Rodger P., Oklahoma City, OK 73120, US; Alvarez, Richard, Edmond, OK 73013, US; Kawar, Ziad, Oklahoma City, OK 73112, US |
| Address for service | | Novartis AG, 4056 BASEL, CH |
33 31 32
| Foreign priority | PRC PRNA PRDA
| US 872170 P Dec 1, 2006
|
| Due date | FT FG | Nov 30, 2025 Annual fee for the 19th year
Patent fees |
| Patent division in charge | | 44 |
21 | File number of protection certificate | ZAKZ | 12 2021 000 019.4 |
97 | EP language of publication | ELANG | EN - Englisch |
84 | Designated EP contracting states | EDS | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR |
| Published EP/WO documents | EPWOPN | Original document:
EP000002662091 Searchable text:
EP000002662091 Original document:
EP000002662091B1 Searchable text:
EP000002662091B1 |
43 | Date of first publication | EVT | Nov 13, 2013 |
| Date of the first transfer into DPMAregister | EREGT | Dec 25, 2013 |
| Date of the (most recent) update in DPMAregister | REGT | Oct 30, 2024 (Show all update days)(Hide all update days)- Oct 30, 2024
- Oct 21, 2023; Jul 6, 2022; Oct 22, 2021; May 25, 2021; May 20, 2021; Apr 14, 2021; Nov 24, 2020; Nov 26, 2019; Aug 14, 2019; Jul 11, 2019; Nov 29, 2018; Sep 20, 2018; Aug 11, 2018; Aug 9, 2018; Apr 6, 2017
- Historical data not available for this/these date(s)
- Dec 25, 2013
- Date of the first transfer into DPMAregister
|
View procedures New applicant/owner details (No.: 6)INID | Criterion | Field | Content
Close details
|
---|
| Type of procedure | VART | New applicant/owner details |
| Legal/procedural status | VST | New applicant/owner details |
| Date of legal/procedural status | VSTT | Apr 13, 2021 |
| Issue number | HN | 20 |
| Year | PJ | 2021 |
| Publication date | VT | May 20, 2021 |
| Type of publication | PART | Bibliographic data |
| Part | HT | Part 3 |
71/73 | Applicant/owner | INH | Novartis AG, Basel, CH; Oklahoma Medical Research Foundation, Oklahoma City, Okla., US |
71/73 | Previous applicant/owner | INHF | Selexys Pharmaceuticals Corporation, Oklahoma City, Okla., US |
| Date of update of the procedure | REGT | May 20, 2021 |